Drugmaker Announces , Promising Results of Potential , Alzheimer's Treatment.<br />On September 28, shares of Biogen and other drugmakers <br />researching Alzheimer's disease skyrocketed after Japan's <br />Eisai Co. announced promising late-stage study results.<br />'Time' reports that the company <br />said its potential treatment appeared <br />to slow the progress of the fatal disease.<br />On September 27, Eisai announced<br />the results of a global study of nearly <br />1,800 people with early-stage Alzheimer's.<br />According to the drugmaker, early results <br />show that the treatment reduced<br />patients' decline by 27% over 18 months.<br />Eisai Co. also announced plans <br />to discuss the trial's full results <br />at a conference in November.<br />'Time' reports that the company plans to publish <br />the findings in a peer-reviewed medical journal.<br />Meanwhile, the company has already sought <br />accelerated approval from the <br />U.S. Food and Drug Administration.<br />'Time' reports that the regulatory agency is expected to make a decision by early 2023.<br />The Alzheimer's Association released <br />a statement calling the study's findings the most <br />encouraging to date for potential treatments.<br />Following the announcement, <br />shares of Biogen Inc. jumped over 50% <br />in premarket trading to top $300
